OSPN OneSpan delivers 20 percent Q4 2025 EPS beat shares rise modestly on upbeat investor reception SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading CCGWW Cheche Group management to share new expansion plans and operational updates with its quarterly earnings release